Related Experiment Video
Updated: Sep 7, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Gastric Neuroendocrine Tumor Treatment and Survival Outcome Depends on Facility Type
Rebecca M Platoff1, Johanna Lou1, Kathryn Bush2
1Department of Surgery, Cooper University Hospital, Camden, NJ, USA.
Background:
Gastric neuroendocrine tumors (gNETs) are rare cancers for which surgery may improve survival. We aim to determine if facility type affects treatment and survival outcomes.
Methods:
The NCDB was queried for patients with gNET from 2004-2016 and stratified into Academic/Research Program (ARP), Community Cancer Program (CCP), Comprehensive Community Cancer Program (CCCP), or Integrated Network Cancer Program (INCP). Overall survival along with clinical and demographic features was compared.
Results:
Median survival was improved in patients treated at an academic program: 137.3 months versus 88.0, 96.3, and 100.2 for CCP, CCCP, INCP, respectively (P < .0001). Patients treated at academic centers were more likely to have surgery (64.2% vs 59.1%, 57.5%, 51.4%, P < .0001). After propensity matching for age, race, grade, stage, insurance status, and comorbidity score, survival benefit from treatment at an academic center remained (P = .03), particularly for patients undergoing surgery (P < .0001) and chemotherapy (P = .04).
Conclusion:
Patients with gNET treated at an academic hospital had improved median survival after propensity matching and may benefit from treatment at academic rather than community medical centers.
Insights
Patients with gastric neuroendocrine tumors (gNETs) treated at academic centers showed improved survival. Academic programs offered better outcomes for gNET treatment, especially with surgery or chemotherapy.
Area of Science:
- Oncology
- Surgical Oncology
- Health Services Research
Background:
- Gastric neuroendocrine tumors (gNETs) are rare malignancies.
- Surgical intervention may enhance survival for gNET patients.
- The impact of treatment facility type on gNET outcomes is not well-established.
Purpose of the Study:
- To investigate the association between healthcare facility type and treatment patterns for gastric neuroendocrine tumors.
- To evaluate the effect of facility type on overall survival in patients with gNETs.
Main Methods:
- Utilized the National Cancer Database (NCDB) to identify patients diagnosed with gNET between 2004 and 2016.
- Stratified patients based on facility type: Academic/Research Program (ARP), Community Cancer Program (CCP), Comprehensive Community Cancer Program (CCCP), and Integrated Network Cancer Program (INCP).
- Compared overall survival and clinical/demographic characteristics, employing propensity score matching for robust analysis.
Main Results:
- Patients treated at academic programs experienced significantly longer median survival (137.3 months) compared to other facility types (88.0-100.2 months; P < .0001).
- Academic centers demonstrated higher rates of surgical intervention (64.2%) compared to CCP, CCCP, and INCP (51.4%-59.1%; P < .0001).
- Survival benefits associated with academic centers persisted after propensity matching, particularly for patients receiving surgery (P < .0001) and chemotherapy (P = .04).
Conclusions:
- Treatment at an academic hospital is associated with improved median survival for patients with gastric neuroendocrine tumors.
- Academic medical centers may offer superior outcomes for gNET management compared to community-based centers.
- The findings suggest a potential benefit for patients seeking gNET treatment at specialized academic facilities.
Related Concept Videos
Cancer Survival Analysis
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Treatment Resistant Cancers
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease

